Cramer Remix

Cramer Remix: What the election means for your money

Cramer: What the election means for your money
VIDEO1:2601:26
Cramer: What the election means for your money

Personal politics aside, Jim Cramer only cares about what Tuesday's elections mean to the market. With the vast array of executives that the "Mad Money" host speaks to on a daily basis, he knows that they are happy about the election results.

What does this mean for the market? Certainty.

Ultimately, people will be willing to pay for more future earnings, because they crave certainty. They just got it in the form of a pro-business Congress and a checkmated president.

Executives will now be willing to take on more risk for their companies, which Cramer translates into more business formation, more growth and more new borrowings.

"That, in a nutshell, is great for the U.S. economy and fabulous for our stock market," said Cramer.

Read MoreCramer: Republican victory adds up in the market

Detroit refinery of the Marathon Petroleum Corp.
Source: Marathon Petroleum Corp.

With the elections finally determining a direction, consumers can now focus on the direction of oil.

Not only does money saved at the pump translate as a benefit to the consumer's pocket, it also is good for an oil refiner such as Marathon Petroleum.

Cramer sat down with Marathon Petroleum Corp CEO Gary Heminger to get his take on what low oil prices could mean for the market and the consumer.

"When I look at what's happening on a same-store basis through our retail chains, we are up 1 percent on same-store basis since gasoline prices started coming below $3," Heminger said. This coincides with Cramer's thesis that oil could be bottoming because there is demand.

Read MoreMarathon CEO to Cramer: 'Low oil is a good thing'

Analysts can come up with a thousand complicated scenarios and fancy charts to estimate how a stock will do. But in Jim Cramer's perspective, it all comes down to executive management. The market has now entered a climate where the management's execution matters most to stock price.

"The abilities of CEOs and their teams to get the job done varies so widely that you have to marvel how ne'er-do-well companies just don't steal top level executives from their competitors," Cramer said.

How about the fact that Amazon is down 24 percent for the year, compared to the monster Alibaba. When Alibaba came public it was at $68 and is now at $109. What is the excuse there? Cramer thinks Alibaba could even go up to $120 and still be considered cheap.

Read MoreCramer calls out top dogs for fizzled stocks

Source: CNBC

On the opposite spectrum, one of the best performers of the year is Actavis. This generic drug company has rallied 46 percent year to date and up 700 percent in almost ten years. Actavis has become a major competitor through gobbling up companies in smart acquisitions. Additionally, Actavis might even be willing to swoop in and rescue Allergan from Valeant's hostile takeover attempts.

To gain further insight, Cramer spoke with Actavis President and CEO, Brent Saunders on whether Actavis could acquire Allergan.

"We won't do any hostile bids that's not who we are. We are about value creation and if we go back to that theme, hostile deals don't create value. Particularly in a specialty pharmaceutical business where people matter," said Saunders.

To get a read on what is happening in the healthcare sector, especially the pharmaceutical industry, Cramer spoke with Fred Hassan, the managing director and managing partner at Warburg Pincus and chairman of Bausch & Lomb.

"This man has more expertise and managing acumen in his pinky than many CEOs have in their whole bodies. So pay attention," said Cramer.

Hassan gave his take on the future of the healthcare sector when he said, "This is going to be the life sciences century….This is because there are three things happening. Number one, there are new technologies in the genome area. You've also got information technology, and then there are academic centers creating a fantastic knowledge on biological systems. These three things are unleashing so much knowledge and there are so many advances going on in cancer and many other areas."

In the Lightning Round, Cramer gave his post-election take on a few caller favorite stocks:

Illumina: "If Illumina gets hit on a day when the market is down because of a broader issue that has nothing to do with life sciences, that's when you pull the trigger to buy. It's a great company, I actually like Thermo-Fisher too"

The GEO Group: "I'm not a big fan of the prison industry, it's contracted by contractors and I'm always afraid one of them is going to lose one and it is unpredictable to me."

Read MoreLightning Round: Time to pull the trigger on this one